drugset / Trial / NCT06308419
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
NaSingle-groupOpen-labelTreatment
Summary
To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.
Timeline
- Start
- 2024-08-14
- Primary completion
- 2029-02-01
- Completion
- 2031-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | nab-sirolimus | Unknown | — | Intravenous |